An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 2 study evaluating the long term safety and tolerability of
GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant
minimal change disease (TR-MCD)